Skip to main content

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article
Pregnancies exposed to ixekizumab (from Eli Lilly Global Safety Database) found 193 pts with psoriasis, PsA, or axSpA who were IXE exposed. Live births reported for 53.8 and 61.1% of known outcomes. No congenital malformations seen. https://t.co/M1rvCH81hT

Dr. John Cush @RheumNow( View Tweet )

Sep 23, 2021

Predictors of Inflammatory Arthritis

Aug 31, 2021

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was

Read Article
Why do they always say larger RCTs are needed? RCT was >1000 and superiority of Bimekizumab to Secukinumab was shown. Maybe it is better to inhibit more than IL17A with added value of IL17F @RheumNow https://t.co/DAwZKxxinM

Janet Pope @Janetbirdope( View Tweet )

Aug 26, 2021
Literature review examined safety of IL-17 inhibitors in 106 controlled RCTs, 40,053 pts. Inflammatory bowel disease was reported in 0.4% of IL-17i Rx patients. (same in 61 uncontrolled RCTs -0.36%). Other AE: diarrhea (2.5%), N/V(0.7%) https://t.co/2wSZQqB1Zs

Dr. John Cush @RheumNow( View Tweet )

Jul 30, 2021
ICYMI: New-Onset IBD & IL-17 Inhibitors: What’s the Risk? https://t.co/zXDQotDiWV Patients w/ inflammatory/autoimmune diseases who initiated treatment w/ IL-17 inhibitors didnt have a higher risk for development of IBD, but only based on the severity of their underlying disease https://t.co/w3IpQkzmn7
Dr. John Cush @RheumNow( View Tweet )
Jul 25, 2021

New-Onset IBD and IL-17 Inhibitors: What Is the Risk?

MedPage Today
Jul 21, 2021

Patients with inflammatory/autoimmune diseases who initiated treatment with interleukin (IL)-17 inhibitors did not have a higher risk for the development of inflammatory bowel disease (IBD), but only after taking into account the severity of their underlying disease, French investigators

Read Article
Study of 33 RCTs, 4544 pts Rx w/ either IL-17 or TNF inhibitors finds lower risk of UVEITIS with anti-TNF mAb (vs PBO OR = 0.46; vs IL-17i OR = 0.34. IL-17 inhibitors are not protective against uveitis https://t.co/AIxgI2qhq9

Dr. John Cush @RheumNow( View Tweet )

Jul 19, 2021

Is Pre-Clinical Spondyloarthritis a Real Risk?

Jul 12, 2021

A study of first-degree relatives (FDRs) of HLA-B27-positive axial spondyloarthritis (axSpA) patients shows clinical or imaging features of spondyloarthritis in up to 32% subjects, regardless of HLA-B27 status.



Historically, it has been suggested there is a 20% risk of ankylosing

Read Article

ICYMI: Psoriatic Disease Management - RNL 2021 Highlights

Jul 08, 2021

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Read Article

ICYMI: New GRAPPA 2021 PsO and PsA Treatment Recommendations

Jul 07, 2021

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients

Read Article

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jun 25, 2021

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article

How do we personalize psoriatic arthritis treatment?

Jun 07, 2021

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?



Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 

Read Article
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 06, 2021
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we
Eric Dein @ejdein1( View Tweet )
Jun 05, 2021
JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA ⭐️achieved JIA ACR response compared to placebo ⭐️⬇️time to flare ⭐️75% with resolution of enthesitis ⭐️0 deaths, AE - minor infections, GI issues, headache Abs#LB0004 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 05, 2021
SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow

Dr. Rachel Tate @uptoTate( View Tweet )

Jun 05, 2021
SPIRIT-P1&P2: IXE is effective in⬇️axial symptoms & improving QoL in active PsA pts with axial involvement. Abstract #POS1045 #EULAR2021 @RheumNow https://t.co/GC78Lmp9cH https://t.co/WfaUqIRrY6
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 05, 2021
PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 05, 2021
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal. #LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 05, 2021
2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 04, 2021

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 04, 2021
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 04, 2021
×